EZH2 and breast cancer: This has significant implications for pathogenesis within the mammary gland, since p53 is a potent tumor suppressor, frequently mutated in breast cancers, and DEK and EZH2 are both highly expressed in breast cancer with oncogenic activity, particularly in triple negative breast cancers (17, 18, 51, 54, 55, 56).